Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 5/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765929 | 0.91 | SLC13A5 (0.79) | SLC13A5ALDH1A1POLBPKMTP53 | |
| SCHEMBL20258706 | 0.90 | SLC13A5 (1.00) | SLC13A5ALDH1A1POLBPKMTP53 | |
| SCHEMBL21766043 | 0.87 | SLC13A5 (0.61) | SLC13A5ALDH1A1POLBPKMTP53 | |
| SCHEMBL20258718 | 0.83 | SLC13A5 (1.00) | SLC13A5ALDH1A1POLBPKMTP53 | |
| SCHEMBL21765928 | 0.82 | TP53 (0.82) | SLC13A5ALDH1A1POLBPKMTP53 | |
| SCHEMBL21766068 | 0.82 | SLC13A5 (0.85) | SLC13A5ALDH1A1POLBPKMTP53 | |
| SCHEMBL21766032 | 0.80 | SLC13A5 (0.77) | SLC13A5ALDH1A1POLBPKMTP53 | |
| SCHEMBL21766012 | 0.80 | SLC13A5 (0.85) | SLC13A5ALDH1A1POLBTP53KMT2A | |
| SCHEMBL21800690 | 0.80 | SLC13A5 (0.85) | SLC13A5ALDH1A1POLBTP53KMT2A | |
| SCHEMBL21800680 | 0.80 | SLC13A5 (0.79) | SLC13A5ALDH1A1POLBPKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793522-B2 | Sulfonamides as inhibitors of the uptake of extracellular citrate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20200062708-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | BOEHRINGER INGELHEIM PHARMA GBMH & CO KG (DE) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062708-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | CS, GLS, GLS2 | SLC13A5 261/4885ALDH1A1 732/4885POLB 2442/4885 |
| US-10793522-B2 | Sulfonamides as inhibitors of the uptake of extracellular citrate | CS, GLS, GLS2 | SLC13A5 261/4885ALDH1A1 732/4885POLB 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.